Bristol Up As New Therapy’s Phase-3 Trial In Lymphoma Is Positive By

© Reuters.

By Dhirendra Tripathi – Bristol-Myers Squibb (NYSE:) shares were up more than 3% Friday as the company’s phase-3 trial of a therapy to treat lymphoma revealed positive results.

Bristol Myers said it’s the first time a treatment beyond chemotherapy and stem cell transplant has demonstrated a benefit in relapsed or refractory large B-cell lymphoma.

Hematopoietic stem cell transplant is considered a gold standard treatment for these patients.

Breyanzi, a cell therapy, was approved by the U.S. Food and Drug Administration in February to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

The company will complete an evaluation of the data and share the results with the health authorities as well as at an upcoming medical conference.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.